Conivaptan: Potential Therapeutic Implications in Heart Failure

Author(s): Stephen Y. Chen, Zuheir Abrahams, George G. Sokos, Wilfried Mullens, Robert Hobbs, David O. Taylor, Gonzalo V. Gonzalez-Stawinski

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 3 , Issue 2 , 2008


Conivaptan, a dual vasopressin receptor antagonist, is a member of an emerging class of medications for the treatment of euvolemic hyponatremia. These agents induce a free-water diuresis as compared to the natriuretic effect of loop diuretics and make them an intriguing prospect for the treatment of congestive heart failure. Article also includes recent patents on this topic.

Keywords: Conivaptan, aquaretic, vasopressin receptor antagonists, congestive heart failure

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [137 - 140]
Pages: 4
DOI: 10.2174/157489008784705403
Price: $65

Article Metrics

PDF: 4